Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017

Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017–2019

Published:2021-01 Issue:1 Volume:99 Page:115195
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Sader Helio S.,Streit Jennifer M.,Mendes Rodrigo E.

Funder

Allergan

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference12 articles.

1. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study);Bai;Expert Rev Anti Infect Ther,2020

2. Important new therapies for methicillin-resistant Staphylococcus aureus;Bassetti;Expert Opin Pharmacother,2019

3. Once-weekly dalbavancin versus daily conventional therapy for skin infection;Boucher;N Engl J Med,2014

4. M07Ed11;Clinical and Laboratory Standards Institute (CLSI),2018

5. M100Ed30;Clinical and Laboratory Standards Institute (CLSI),2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings;The Journal of Emergency Medicine;2024-08

2. Dalbavancin utilization registry investigating value and effectiveness (DRIVE): Outcomes report on real-world use;Clinical Infection in Practice;2024-01

3. Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus;Journal of Bone and Joint Infection;2023-06-28

4. Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) infection: what are the challenges?;Expert Opinion on Pharmacotherapy;2023-01-03

5. Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus;International Journal of Antimicrobial Agents;2022-10